戻る
GT Biopharma Inc (GTBP)価格
GTBP 株価推移チャート
GTBP 財務
GT Biopharma Inc
$0.71
-2.1%
$-0.01
終値： Jan 21, 16:00:00 GMT-5
$0.69
-1.95%
$-0.01
アフターマーケット：Jan 21, 20:00:00 GMT-5
主要データ
前終値
$0.7253
始値
$0.72
当日レンジ
$0.6808 - $0.7253
52週レンジ
$0.54 - $3.85
取引高
853.4K
平均取引高
1.3M
1株当たり利益(TTM)
-5.70
配当利回り
--
時価総額
$7.4M
GTBPとは何ですか？
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.